Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 8 No. 5, May 2007
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J. F.
Right arrow Articles by Druzin, M. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Smith, J. F., Jr
Right arrow Articles by Druzin, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

NeoReviews Vol.8 No.5 2007 e206
© 2007 American Academy of Pediatrics

Perinatal Implications of the Antiphospholipid Syndrome

James F. Smith, Jr, MD*
Maurice L. Druzin, MD

* The Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, Calif

Since their initial recognition 100 years ago, antiphospholipid antibodies and the syndrome associated with them have provided clinical, laboratory, and experimental challenges, and their specific pathogenesis in pregnancy-related complications remains an evolving story. Antiphospholipid syndrome (APS) involves arterial thrombosis, venous thrombosis, or recurrent pregnancy loss in association with the laboratory demonstration of the presence of antiphospholipid antibodies. The two most commonly associated antibodies are anticardiolipin antibodies and the lupus anticoagulant. APS can have a direct negative effect on the developing placenta in pregnancy, and maternal thrombosis may result from the additive thrombogenic combination of antiphospholipid antibodies and the pregnancy state. Pregnancy complications associated with APS include recurrent first-trimester miscarriage, second- or third-trimester fetal death, and preterm delivery. Treatment of APS in pregnancy is based primarily on consensus and expert opinion.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Academy of Pediatrics.